Showing results (61-70 of 89) with videos related to
Sort By:
Pageof 9
Current Oncology (Toronto, Ont.)|December 24, 2025
Real-World Predictors of Survival in CDK4/6 Inhibitor-Treated Metastatic Breast Cancer: The Significance of ER Expression Level and Treatment NaivetyBüşra Bülbül, Bekir Ucun, Can Cangür, et al.Medicina (Kaunas, Lithuania)|May 27, 2026
Does the Duration of FLOT Infusion Change the Outcome of Perioperative Treatment for Gastric Cancer? Comparing 24- and 48-h InfusionsHacer Demir, Canan Yıldız, Yusuf İlhan, et al.Medicina (Kaunas, Lithuania)|January 28, 2026
The Impact of Concurrent Proton Pump Inhibitors on Nivolumab Response in Metastatic Non-Small Cell Lung Cancer: A Multicenter Real-Life StudyEngin Hendem, Mehmet Zahid Koçak, Ayşegül Merç Çetinkaya, et al.Breast Cancer (Dove Medical Press)|March 23, 2026
Endocrine Therapy versus Chemotherapy After CDK4/6 Inhibitor Progression in HR+/HER2- Metastatic Breast Cancer: A Multicenter Real-World Study from TurkeyCan Cangür, Büşra Bülbül, Irem Turgut Yeğen, et al.Journal of Cancer Research and Clinical Oncology|May 15, 2023
The effect of concomitant proton pump inhibitor use on survival outcomes of Nivolumab-treated renal cell carcinoma patients: a multicenter studyMuzaffer Uğraklı, Mehmet Zahid Koçak, Gülhan Dinç, et al.Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|April 4, 2019
A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG)Serkan Degirmencioglu, Ozgur Tanriverdi, Serkan Menekse, et al.Asian Pacific Journal of Cancer Prevention : APJCP|June 25, 2015
Adult Urological Soft Tissue Sarcomas: A Multicenter Study of the Anatolian Society of Medical Oncology (ASMO)Olcun Umit Unal, Ilhan Oztop, Serkan Menekse, et al.Scientific Reports|March 27, 2026
The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world, multicenter, retrospective studyAhmet Oruç, İlknur Deliktaş Onur, Galip Can Uyar, et al.Experimental Hematology & Oncology|June 9, 2026
Statins enhance trastuzumab deruxtecan efficacy: preclinical synergy in HER2-negative models and clinical benefit in HER2-positive metastatic breast cancerTaha Koray Sahin, Cemal Orhan, Ibrahim Hanifi Ozercan, et al.Journal of Clinical Medicine|May 27, 2026
Prognostic and Treatment-Specific Predictive Implications of HER2 Expression in RAS Wild-Type Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World StudyÖzlem Özdemir, Damla Günenç, Halil Taşkaynatan, et al.Pageof 9